Large deletions (>50 bp) in the F9 gene, 90% of which are associated with the severe phenotype, occur in approximately 5% of patients with severe HB and significantly increased risks for developing inhibitors5, 7, 8. This evidence concerns the gene F9 and hemoglobin measurement.